Five-year data from the KEYNOTE-048 trial support the use of pembrolizumab and pembrolizumab-chemotherapy as standards of care, researchers wrote.

Teos and GSK were the last to report a new setback in TIGIT targeting for non-small cell lung cancer patients. Read why I am ...

The first patient has received CX-801 plus Keytruda in a phase 1 trial for metastatic melanoma, aiming to assess safety and ...

In June 1884, he was diagnosed with carcinoma of the right tonsillar pillar, a type of mouth cancer, commonly known as throat ...

In a new study published in Nature, researchers at the University of Chicago Medicine Comprehensive Cancer Center explore a ...

Def Leppard guitarist Vivian Campbell has returned to the stage eight months after he underwent a bone marrow transplant in ...

GT Biopharma (NASDAQ: GTBP) just initiated the dosing in Cohort 2 of its Phase 1 dose escalation trial evaluating GTB-3650 for the treatment of relapsed or refractory (r/r) CD33 expressing hematologic ...

The Phase 1 trial, fully funded by a U.S. Department of Defense grant awarded to Cleveland Clinic, is nearing enrollment completion. Monitoring and data analysis will continue over the next three to ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") will present 16 abstracts featuring new data across its approved cancer therapies at the 2025 American Society of ...

HURA READ THE FULL HURA RESEARCH REPORT Operational and Financial Results On May 15th, 2025, TuHURA Biosciences, Inc. (NASDAQ:HURA) reported first quarter 2025 financial and operational results and ...